小分子大豆肽联合中医内科治疗在原发性肾病综合征中的应用效果
|
张丽，王蒙
|
临沂金锣医院，山东临沂，230036
|
摘要：目的 探究原发性肾病综合征治疗中小分子大豆肽联合中医内科治疗的应用效果。方法 随机选择本院 2023 年 1 月～2024 年 12 月间收治的原发性肾病综合征患者进行研究。共计 100 例患者，并以随机数字表法分 2 组。对照组 50 例，予以常规激素治疗。观察组 50 例，联用小分子大豆肽+中医内科治疗。比较两组治疗效果。结果 观察组临床有效率 98.00%高于对照组（χ
2=4.891；P＜0.05）。观察组不良反应发生率 4.00%低于对照组（χ
2=4.000；P＜0.05）。观察组治疗后 24 h尿蛋白定量（0.40±0.11）g、尿素氮（6.20±0.88）mmol/L、血肌酐（75.23±12.84）μmol/L低于对照组，白蛋白（35.77±3.14）g/L高于对照组（t=19.777；t=6.771；t=5.226；t=8.893；P＜0.05）。结论 原发性肾病综合征中，小分子大豆肽联合中医内科治疗可进一步改善患者肾功能，提高疗效，还可缓解激素治疗的副作用，值得推广。
关健词：原发性肾病综合征；小分子大豆肽；中医内科；临床疗效；肾功能；不良反应
|
Application Effect of Small Molecular Soybean Peptide Combinedwith Internal Medicine of Traditional Chinese Medicine in PrimaryNephrotic Syndrome
|
Li Zhang,Meng Wang
Linyi Jinluo Hospital, Linyi Shandong 230036, China
|
Abstract：Objective To explore the application effect of small molecular soybean peptide combined with Internal Medicine of
Traditional Chinese Medicine (TCM) in the treatment of primary nephrotic syndrome. Methods One hundred patients with
primary nephrotic syndrome admitted to our hospital from January 2023 to December 2024 were randomly selected for the study
and divided into two groups using a random number table method. The control group (n=50) received conventional hormone
therapy. The observation group (n=50) received a combination of small molecular soybean peptide and Internal Medicine of
TCM. The therapeutic effects of the two groups were compared. Results The clinical effective rate in the observation group was 98.00%, which was higher than that in the control group (χ2=4.891; P < 0.05). The incidence of adverse reactions in the observation group was 4.00%, lower than that in the control group (χ2=4.000; P < 0.05). After treatment, the 24-hour urinary
protein quantification (0.40±0.11) g, urea nitrogen (6.20±0.88) mmol/L, and serum creatinine (75.23±12.84) μmol/L in the observation group were lower than those in the control group, while albumin (35.77±3.14) g/L was higher than that in the
control group (t=19.777; t=6.771; t=5.226; t=8.893; P < 0.05).Conclusion For primary nephrotic syndrome, the combination
of small molecular soybean peptide and Internal Medicine of TCM can further improve patients' renal function, enhance
therapeutic efficacy, and mitigate the side effects of hormone therapy, making it worthy of promotion.
Keywords : Primary nephrotic syndrome; Small molecular soybean peptide; Internal Medicine of Traditional Chinese Medicine;Clinical efficacy; Renal function; Adverse reactions
参考文献
[1] 肾脏创新与转化联盟肾脏病领域“十大创新方向”专家组.肾脏病领域"十大创新方向"中国专家共识(2024 年版)[J].中华肾脏病杂志,2024,40(5):426-430.
[2] 陈淑园,许筠,张茹,等.成人原发性肾病综合征激素维持治疗阶段中医体质与证型的相关性分析[J].中医药临床杂志,2023,35(7):1365-1370.
[3] 杜罕,马文玲,祝巍.保肾汤联合激素治疗原发性肾病综合征合并急性肾损伤临床研究[J].新中医,2023,55(23):106-109.
[4] 蒋倩楠,何国友,宋艳清,等.探讨小分子大豆肽联合免疫抑制剂治疗原发性肾病综合征的临床疗效[C]//南京康复医学会.第六届全国康复与临床药学学术交流会议论文集（二）.临沂金锣医院,2023:822-825.
[5] 刘小龙,金钟大.麻黄连翘赤小豆汤合防己黄芪汤加减治疗原发性肾病综合征临床观察[J].四川中医,2021,39(11):142-145.
[6] 陈高建,冯向峰,杜海波,等.中医辨证治疗老年原发性肾病综合征的效果分析[J].当代医药论丛,2022,20(13):155-157.
[7] 刘书真,谢泉琨,王永磊,等.补肾纳气方联合糖皮质激素治疗原发性肾病综合征临床研究[J]. 新中医,2022,54(21):105-108.
[8] 孔玥潓.大豆肽对慢性高尿酸血症小鼠尿酸转运蛋白和尿酸代谢的影响[D].吉林:吉林农业大学,2023.
|
|
|
论文收录证明 / 文献检索报告
Document Retrieval Certificate / Proof of Publication Indexing
作者贡献声明 / 贡献确认书
Author Contribution Statement / Certificate of Authorship Contribution
同行评审报告 / 评审意见
Peer Review Report / Peer Review Comments
利益冲突
Conflict of Interest
作者声明不存在任何利益冲突。
The author declares no conflict of interest.
|
|
